Refractory Marginal Zone Lymphoma Clinical Trials in Hangzhou, Zhejiang
2 recruitingHangzhou, Zhejiang, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.324 enrolled19 locationsNCT06082102
Recruiting
Phase 4
Clinical Study of OR for Second-line Treatment of Refractory MZL
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng39 enrolled3 locationsNCT06134284